Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...
ZME Science on MSN11d
A Simple Blood Test Called PAC-MANN Could Detect Pancreatic Cancer Early and Save Thousands of Lives
Pancreatic cancer is one of the deadliest and most difficult-to-detect forms of cancer. It kills nearly half a million people ...
Adaptive Biotechnologies launches assay enhancements for clonoSeq
Adaptive Biotechnologies (ADPT) has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse ...
New Test Detects Early Pancreatic Cancer with 85% Accuracy — and Researchers Say It Costs ‘Less Than a Penny’
The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the blood of someone who doesn’t have the disease. When used alongside the ...
PipelineReview.com1d
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...
GlobalData on MSN5mon
Roche’s VENTANA CLDN18 assay gains CE mark
Gastric cancer, the fifth most common cancer globally, poses a significant challenge due to late diagnosis and has a low ...
Medindia2d
ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE� (mirvetuximab soravtansine-gynx) in women with folate ...